Target Name: LMO1
NCBI ID: G4004
Review Report on LMO1 Target / Biomarker Content of Review Report on LMO1 Target / Biomarker
LMO1
Other Name(s): RBTN1 | cysteine-rich protein TTG-1 | LMO-1 | T-cell translocation protein 1 | LIM domain only 1 (rhombotin 1) | LIM domain only 1, transcript variant 1 | TTG1 | RHOM1 | MGC116692 | Rhombotin-1 | LMO1 variant 1 | Rhombotin-1 (isoform a) | T-cell translocation gene 1 | LIM domain only 1 | RBTN1_HUMAN | Cysteine-rich protein TTG-1 | LIM domain only protein 1

Understanding LMO1: A Potential Drug Target and Biomarker for Neurological Disorders

LMO1 (RBTN1), a protein located in the brain, has been identified as a potential drug target and biomarker for various neurological and psychiatric disorders. its one of the best candidate for a potential therapeutic intervention in the field of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

LMO1 is a scaffold protein that is involved in the formation and maintenance of the blood-brain barrier. The blood-brain barrier is a critical barrier that separates the brain from the surrounding blood vessels, and it plays a crucial role in protecting the brain from harmful substances and diseases. However, in the case of neurodegenerative diseases, the blood-brain barrier becomes compromised, leading to the entry of toxic substances and the progressive loss of brain cells.

LMO1's role in the formation and maintenance of the blood-brain barrier makes it an attractive target for therapeutic intervention. By targeting LMO1, researchers hope to reduce the risk of neurodegenerative diseases and slow down the progression of these conditions.

One of the key challenges in studying LMO1 is its complex structure. LMO1 is a transmembrane protein that spans the brain surface and is also involved in the formation of other brain structures. This makes it difficult to study and understand its function. However, research using techniques such as immunofluorescence and biochemical assays is ongoing to gain a better understanding of LMO1's role in the brain.

Another challenge is the lack of animal models that closely mimic the human brain. Many neurodegenerative diseases are difficult to study in animals because the symptoms and conditions of these diseases are often difficult to replicate in animals. However, efforts are being made to develop more realistic animal models that can be used to study LMO1 and its potential therapeutic interventions.

In addition to its potential therapeutic applications, LMO1 is also a potential biomarker for neurodegenerative diseases. The loss of LMO1+ cells in the brain is a hallmark of neurodegenerative diseases, and its levels can be used as a diagnostic marker for these conditions. This makes LMO1 an attractive target for researchers who are looking for new diagnostic biomarkers for neurodegenerative diseases.

In conclusion, LMO1 is a protein that has the potential to be a drug target and biomarker for various neurological and psychiatric disorders. Further research is needed to fully understand its role in the formation and maintenance of the blood-brain barrier and its potential therapeutic applications. With the development of more realistic animal models and better diagnostic biomarkers, LMO1 could potentially be a valuable tool in the fight against neurodegenerative diseases.

Protein Name: LIM Domain Only 1

Functions: May be involved in gene regulation within neural lineage cells potentially by direct DNA binding or by binding to other transcription factors

The "LMO1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LMO1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

LMO2 | LMO3 | LMO4 | LMO7 | LMO7-AS1 | LMO7DN | LMOD1 | LMOD2 | LMOD3 | LMTK2 | LMTK3 | LMX1A | LMX1B | LMX1B-DT | LNC-LBCS | LNCAROD | LNCARSR | LNCATV | LNCNEF | LNCOC1 | LNCOG | LNCPRESS1 | LNCRI | LNCRNA-ATB | LNCRNA-IUR | LNCTAM34A | LNP1 | LNPEP | LNPK | LNX1 | LNX1-AS1 | LNX2 | LOC100127946 | LOC100127955 | LOC100128002 | LOC100128028 | LOC100128050 | LOC100128059 | LOC100128079 | LOC100128093 | LOC100128164 | LOC100128242 | LOC100128288 | LOC100128317 | LOC100128361 | LOC100128398 | LOC100128494 | LOC100128593 | LOC100128770 | LOC100128966 | LOC100128988 | LOC100129034 | LOC100129098 | LOC100129148 | LOC100129175 | LOC100129203 | LOC100129215 | LOC100129316 | LOC100129381 | LOC100129434 | LOC100129455 | LOC100129534 | LOC100129603 | LOC100129697 | LOC100130000 | LOC100130207 | LOC100130285 | LOC100130298 | LOC100130331 | LOC100130452 | LOC100130463 | LOC100130548 | LOC100130587 | LOC100130691 | LOC100130698 | LOC100130744 | LOC100130748 | LOC100130872 | LOC100130899 | LOC100130938 | LOC100130987 | LOC100130992 | LOC100131096 | LOC100131107 | LOC100131257 | LOC100131289 | LOC100131372 | LOC100131496 | LOC100131532 | LOC100131626 | LOC100131635 | LOC100131859 | LOC100131877 | LOC100131943 | LOC100132004 | LOC100132062 | LOC100132077 | LOC100132078 | LOC100132249 | LOC100132287